Quantcast
Last updated on April 18, 2014 at 7:49 EDT

Latest gabapentin Stories

2013-02-13 16:26:49

NEWARK, Calif., Feb. 13, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will release fourth quarter fiscal year 2012 financial results after the market closes on Wednesday, February 20, 2013. The Company will host a conference call beginning at 4:30 pm Eastern time, 1:30 pm California time to discuss its results. Participants can access the call by dialing 877-317-6789 (United States) or 412-317-6789 (international). The conference call will also be...

2012-12-26 16:20:51

NEWARK, Calif., Dec. 26, 2012 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced that its lawsuits against two filers of Abbreviated New Drug Applications (ANDAs) for Gralise(®) (gabapentin) have been dismissed. Watson Laboratories has withdrawn its Gralise ANDA. Par Pharmaceutical has amended its Gralise ANDA and is no longer seeking approval of the ANDA prior to the expiration of Depomed's patents listed for Gralise in the FDA publication commonly known as the Orange Book....

2012-12-03 16:24:22

NEWARK, Calif., Dec. 3, 2012 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced that it will be presenting at the Oppenheimer 23rd Annual Healthcare Conference at the Waldorf Astoria Hotel in New York City. The presentation at the Oppenheimer conference is scheduled for 10:35 am EST (7:35 am PST) on Wednesday, December 12, 2012. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording...

2012-11-19 16:29:51

MENLO PARK, Calif., Nov. 19, 2012 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the Piper Jaffray 24(th) Annual Healthcare Conference at the Palace Hotel in New York City. The presentation at the Piper conference is scheduled for 10:00 am EST (7:00 am PST) on Tuesday, November 27, 2012. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the...

2012-11-06 08:27:51

MENLO PARK, Calif., Nov. 6, 2012 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the Lazard Capital Markets 9(th) Annual Healthcare Conference in New York City. The presentation at the Lazard conference is scheduled for 10:30 am EST (7:30 am PST) on Wednesday, November 14, 2012. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the...

2012-10-29 07:25:45

MENLO PARK, Calif., Oct. 29, 2012 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will release third quarter fiscal year 2012 financial results after the market closes on Monday, November 5, 2012. The Company will host a conference call beginning at 5:00 pm Eastern time, 2:00 pm California time to discuss its results. Participants can access the call by dialing 877-317-6789 (United States) or 412-317-6789 (international). The conference call will also be available via a...

2012-10-15 07:29:52

SAN FRANCISCO, Oct. 15, 2012 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that preclinical data for NKTR-171, a new investigational drug candidate to treat neuropathic pain, was presented at the 41(st) Annual Meeting of the Society for Neuroscience: Neuroscience 2012. NKTR-171 is a novel sodium channel blocker designed to act in the periphery in order to treat neuropathic pain while avoiding the serious central nervous system (CNS) side effects associated with current...

2012-10-15 07:28:58

MENLO PARK, Calif., Oct. 15, 2012 /PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO) today announced that its New Drug Application (NDA) for Serada® has been accepted for filing by the U.S. Food and Drug Administration (FDA). In addition, the FDA has informed the company that the FDA's Reproductive Health Drugs Advisory Committee will discuss the Serada NDA at an Advisory Committee meeting tentatively scheduled for March 4, 2013. The NDA will be subject to a standard review and will have a...

2012-10-12 15:22:01

BOCA RATON, Fla., Oct. 12, 2012 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announced today that it has entered into an agreement with Marksans Pharma, Ltd to market its Abbreviated New Drug Application (ANDA) for Gabapentin Capsules, the generic version of Neurontin® Tablets by Pfizer. The product was approved by the U.S. Food and Drug Administration (FDA) on July 21, 2011. Under the terms of this agreement, Marksans Pharma will manufacture and supply the product to Breckenridge...

2012-10-03 02:27:32

MENLO PARK, Calif., Oct. 3, 2012 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) announced today that it is presenting two abstracts from its Phase 3 clinical trial, BREEZE 3, at this week's 23(rd) Annual Meeting of the North American Menopause Society (NAMS) in Orlando, FL. The data showed that Serada(®), Depomed's investigational non-hormonal extended-release formulation of gabapentin, may help manage menopausal hot flashes. "Hot flashes are a disruptive problem affecting as many as...